BAGSVAERD, Denmark, June 6, 2016 /PRNewswire/ -- Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from 10-14 June.
Following are key highlights that will be presented at the meeting:
12 June, 8.30 am CDT, oral presentation
12 June, 9.00 am CDT, oral presentation
12 June, 12.00 pm CDT, poster presentation
12 June, 3.00 pm CDT and 13 June, 8.45 am CDT, oral presentations
12 June, 2.45 pm CDT, oral presentation
13 June, 2.15 pm CDT, oral presentation
11 June, 12.30 pm CDT, moderated poster discussion; 13 June, 12.00 pm CDT, poster presentation
"ADA 2016 will be a landmark congress for Novo Nordisk. This year, we have an unprecedented amount of key clinical data on our new insulins and GLP-1, and we look forward to sharing it all with the medical and scientific community," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The presented research demonstrates advances in several areas of diabetes, underscoring our focus on developing innovative treatments with the potential to improve the lives of people with diabetes."
The above abstracts are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts please visit: http://www.abstractsonline.com/pp8/#!/4008.
This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit http://www.novonordisk.us.
About Novo Nordisk
Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people with other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has more than 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
Tresiba® and Victoza® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2016 Novo Nordisk All rights reserved. USA16HCP01208 June 2016
SOURCE Novo Nordisk